Navigation Links
Dragon Pharma reports 2010 first quarter financial results
Date:5/17/2010

VANCOUVER, May 17 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company" TSX: DDD; OTCBB: DRUG), an international manufacturer of antibiotics, today announced its financial results for the first quarter ended March 31, 2010.

Results for the Quarter Ended March 31, 2010

The Company recorded $49.06 million of revenues for the quarter ended March 31, 2010, representing 33% growth from $36.96 million for the same period of 2009. Net income was $1.58 million, representing 9% increase from $1.45 million for the same period of 2009. Earnings per share (basic and diluted) were $0.02 compared to $0.02 for the same period of 2009.

Sales from the Penicillin Division increased 17% from the same period of 2009 to $14.69 million, accounting for 30% of the Company's total revenues for the first quarter of 2010. The Company expanded its production capacity of Clavulanic Acid in the fourth quarter of 2009 to 135 tons, therefore during the first quarter ended March 31, 2010, sales volume increased 42% to 31 tons from 22 tons for the same period of 2009. Sales from Cefalexin and Cefadrozil, two other main products in the division, decreased 3% from the same period of 2009 mainly due to lower selling prices resulting from oversupply of such products in the Chinese market.

Sales from the Cephalosporin Division increased 41% from the same period of 2009 to $34.37 million, accounting for 70% of the
'/>"/>

SOURCE Dragon Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
2. Strong Demand Pushes up Both Prices and Sales Volumes for Dragons Main Products
3. Dragon Announces R&D Achievement in Biotech Manufacturing Process
4. Dragon announces new product launch; increase in annual production output capacity
5. Dragon retains leading investor relations firm
6. Dragon Pharma announces 2007 full year financial results
7. 3SBio Inc. to Present at The Oppenheimer 2nd Annual China Dragon Call Conference
8. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
9. Dragon Pharma Announces Results of the Annual General Meeting
10. Dragon to Present at BioContact Quebec 2008
11. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Research and Markets has ... 2014-2018" report to their offering. ... study of the genetic material or genomes of an ... for the discovery and development of diagnostic and therapeutic ... conditions. Genomics is supported by three major product segments: ...
(Date:7/31/2014)... and SHENZHEN, China , July 31, ... the purchase of an Irys™System by ... BioNano,s platform to enable comprehensive exploration of human structural ... various organisms of interest, including those where no reference ... to develop new methods for multiplexing on the Irys ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Although ... of the first transcriptome-wide analyses appearing around 2008, ... assay for RNA measurement. In the last several ... more specific, work with smaller input amounts, process ... (eg, blood samples). On the bioinformatics side, there ...
(Date:7/31/2014)... 2014 The Kidney Cancer Association (KCA) has ... news magazine, Kidney Cancer News. , Bill Bro, KCA ... website maintained by an international news organization. When we began ... viewers.” , This month’s program highlights news of an enzyme ... in a recent study. Kidney Cancer News also presents a ...
Breaking Biology Technology:Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2
... , Multiporator , , , , , , , ... Protocol No. 4308 915.032 03/2000 , , , ... , , Cell line , ... Transfection with , Plasmid pEGFP-N1 (in bidistilled H 2 O), ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.508 12/2001 , ... , , , , ... , Cell type , Bacteria, gram ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.538 04/2002 , , , ... , , Microorganism , ... Cell type , Bacteria, gram positive, , ...
Cached Biology Technology:BW 5147 2Brucella abortus 2Bifidobacterium animalis 2
(Date:7/31/2014)... the National Science Foundation (NSF), counters a widely-held ... warming, indicating instead that certain Arctic lakes store ... atmosphere. , The study, published this week ... thermokarst lakes, which occur as permafrost thaws and ... water, converting what was previously frozen land into ...
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... 100 percent of animal models against the highly infectious ... an intestinal disease that kills approximately 30,000 Americans annually. ... Infection and Immunity . , In the study, ... the purified toxins produced by C. difficile , ... laboratory model that mimics the human disease, after only ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2
... release is available in German . , ... - a North African bird species with a very ... from attractive males of the same species positively affects ... highly displaying male birds in the experiment were more ...
... Institute of Standards and Technology (NIST) scientists have moved a ... blood test that can scan for thousands of disease markers ... has learned how to decode the electrical signals generated by ... artificial cell membrane. Nanopores are not new themselves; for ...
... of atherosclerosis has allowed researchers to identify a host of ... the process, before a plaque appears in the affected blood ... Blood, the journal of the American Society of Hematology. ... disturbances in the patterns of blood flow in an artery ...
Cached Biology News:Pleasing to the eye 2Pleasing to the eye 3NIST team advances in translating language of nanopores 2To predict atherosclerosis, follow the disturbed blood flow 2
... EC570-90 is a compact, lightweight, high current power ... or 2500 milliamps. It is an excellent choice ... gels. It is also ideal for all types ... be set to automatically end a run and ...
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
... use in Refrigerated Vapor Trap Models RVT100, ... (UVS) Models UVS400, UVS400A and UVS800DDA., A ... for use for temperatures ranging from -105 ... thermal stability and does not evaporate. Far ...
Acetate Plate Sealers 100/Box...
Biology Products: